LONDON (Alliance News) - GlaxoSmithKline PLC on Tuesday said data from the early-stage Garnet clinical study had promising results for the use of Dostarlimab in patients with endometrial cancer.
Dostarlimab was developed by Tesaro Inc, which was acquired by FTSE 100-listed GSK for USD5.1 billion in December.
The phase one/two stage study found a clinically meaningful and durable response rate to Dostarlimab in women with advanced or recurrent endometrial cancer.
GSK intends to file a biologics licence application with the US Food & Drug administration for Dostarlimab in endometrial cancer patients by the end of 2019.
Tesaro President & Chief Operating Officer Mary Lynne Hedley said: "Currently, treatment options for women with advanced or recurrent endometrial cancer are limited, with only one FDA-approved agent for a subset of these patients.
"We intend to use these and other data from the Garnet study to seek regulatory approval of dostarlimab to potentially address the critical unmet treatment needs of women whose disease has progressed," Hedley added.
"The data presented today evaluating Dostarlimab in women with recurrent/advanced endometrial cancer, combined with earlier data in patients with non-small cell lung cancer, reinforces the potential of Dostarlimab in treating patients with a variety of solid tumours", Hedley continued.
Shares in GSK closed down 0.6% at 1,503.20 pence on Tuesday.
Glaxosmithkline (GSK)